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ABSTRACT 
Objective: Several 3(rd) generation inhibitors are being developed for the treatment of patients with Chronic myelogenous leukemia (CML). The 
present work mainly aims to discover novel small molecular inhibitors against important molecular target T3151 ABL mutant involved in leukemia.  
Methods: Docking study was carried out and the binding affinity of the proteins with the phenothiazine compounds 3a-h and 7a-c was measured. 
The docking scores of the N-acylated compounds 7a-c are higher than 3a-h. The drug likeliness of these compounds was tested by the Lipinski’s rule 
of five. The phenothiazine compounds with good docking scores and 7a-c were synthesized and screened by in-vitro methods for inducing 
antiproliferative effect by trypan blue and MTT assay and induction of apoptosis in K562 cells.  
Results: All the N-acylated compounds and, in particular, 7c with a chloro substituent in the para position of the phenyl ring appeared to be most 
potent molecule with an IC50 value of 32.44 and 24.01(µg/ml) by trypan blue and MTT assay respectively. Further, a dose-dependent increase in 
LDH release was observed, confirming the antiproliferative potential of the compounds. 
Conclusion: The compounds 7a-c was tested for antiproliferative effect against K562 cell lines by MTT assay LDH assay and Trypan blue assay. All 
the compounds 7a-h behaves as 3(rd) generation inhibitors for the treatment of patients with Chronic myelogenous leukemia (CML). These can act 
as a template for the further development and optimization studies. 
Keywords: Synthesis, Phenothiazine, Cyclohexanone derivatives, Chronic myelogenous leukemia, Molecular docking, Anti-proliferative activity. 
 
INTRODUCTION 
In the post-genomic era, anti-cancer drug discovery aims to discover 
small molecules that modulate the activity of key therapeutic targets 
responsible for carcinogenesis. Computer-aided design [1-6] is being 
utilized to expedite and facilitate the lead molecule identification [7-12]. 
It reduces the size of chemical space and thereby allows to focus on more 
promising candidates for lead discovery and optimization [13-17]. 
Chronic myelogenous leukemia (CML) is a hematological stem cell 
disorder caused by increased and unregulated growth of myeloid cells 
in the bone marrow [18,19], and the accumulation of excessive white 
blood cells. Abelson tyrosine kinase (ABL) [20] is a non-receptor 
tyrosine kinase involved in cell growth and proliferation and is usually 
under tight control. However, it was reported that majority of CML 
patients have the ABL gene from chromosome 9 fused with the 
breakpoint cluster (BCR) gene from chromosome [21], resulting in a 
short chromosome known as the Philadelphia chromosome [22-25]. 
This Philadelphia chromosome is responsible for the production of 
BCR-ABL, a constitutively active tyrosine kinase that causes 
uncontrolled cellular proliferation [26, 27]. An ABL inhibitor, imatinib, 
is used at present as first line therapy. However, a high percentage of 
clinical relapse has been observed due to long-term treatment with 
imatinib [28]. A majority of these relapsed patients have several point 
mutations at and around the ATP binding pocket of the ABL kinase 
domain in BCR-ABL [29]. In order to address the resistance of mutated 
BCR-ABL to imatinib [30], 2(nd) generation inhibitors such as 
dasatinib, and nilotinib [31] were developed [32,33]. All of the BCR-
ABL mutants are inhibited by the 2(nd) generation inhibitors with the 
exception of the T315I mutant. Several 3(rd) generation inhibitors are 
being developed to target the T315I mutation [34].  
This prompted us to try some of the phenothiazine derivatives 
which are synthesized in our laboratory in order to address the 
resistance of mutated BCR-ABL to imatinib and 2(nd) generation 
inhibitors such as dasatinib, and nilotinib. If the present work is 
encouraging it is anticipated that additional drugs will be available 
for the treatment of patients with the mutated BCR-ABL-T315I. The 
success of these inhibitors will have greater implication not only in 
CML, but also in other diseases driven by kinases where the mutated 
gatekeeper residue plays a major role.  
MATERIALS AND METHODS 
Docking studies 
Active site prediction 
The catalytic sites of tyrosine kinase Receptor along with area and 
volume of binding pocket was carried out with Meta Pocket 2.0 
Finder program [35]. In the binding pocket the Active site residues 
of T3151 ABL mutant are Ala350, Ala365, Ala366, Asn297, Arg483, 
Asp381, Asp421, Asp482, Cys305, Cys369, Gln477, Gly303, Gly372, 
Gly383, Gly426, Ile315, Ile347, Leu302, Leu364, Met458, Ser265, 
Thr267, Trp405, Tyr320 and Val299.  
Preparation of the protein and the compounds 
The three-dimensional crystal structure of the T3151 ABL mutant in 
complex with the aura kinase inhibitor was retrieved from the 
Protein Data Bank [36]. The complexes bound to the receptor 
molecule, all the heteroatoms, and the non-essential water 
molecules were removed and finally hydrogen atoms were merged 
to the target receptor molecule using Argus Lab [11]. The series of 
phenothiazine compounds synthesized in our laboratory 7a-h forms 
the database. The compound structures were drawn using 
ChemDraw software and converted to mol format with the standard 
settings and further used for docking studies.  
Molecular docking 
The molecular docking program Aurgus Lab 4.0 software which is 
most commonly available software was used to perform the virtual 
screening. The receptor was defined from the crystallographic 
coordinates of the ligand. The binding site atoms were further 
defined from a file listing the cavity atoms. Dockings were 
performed under ‘Standard default settings’ mode. All the 
parameters used in Argus lab docking were selected by default. 
Calculation type was set to “dock” mode and “flexible mode” was 
selected for the ligand. The docking results were analyzed using 
PYMOL (TM) software, which allows visualization of the protein-
ligand docking and calculation of several descriptors such as feasible 
hydrogen bonding between the protein and the ligand. The scores 
were calculated and presented in the table 1. Least energy indicated 
the easy binding character of ligand and receptor.  
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Synthesis of the compounds 7a-h  
Chalcones and their cyclohexonones were prepared as per the 
procedure we have already reported [37] and characterised. 0.001 
mole of 2-acetyl phenothiazine 1 was dissolved in 25 ml methanol 
and 0. 001 moles of different substituted benzaldehydes 2a-h were 
added, followed by the addition of 5 ml aqueous solution of NaOH 
(5%) and heated for 6 h with constant stirring in a magnetic stirrer. 
The reaction was monitored by TLC. After completion of the 
reaction, the reaction mixture was poured into ice-cold water, 
neutralized with con. HCl and left overnight in a refrigerator. The 
resulted precipitate was filtered, dried and the purity of the 
compounds was checked by TLC using chloroform as the solvent. 
The compounds were purified by column chromatography using 
silica gel (60-120 mesh). 
Cell culture 
K562 cell line purchased from NCCS Pune was maintained in 
Dulbecco’s modified eagles media (HIMEDIA) supplemented with 
10% FBS (Invitrogen) and grown to confluency at 37 °c in 5 % CO2 
(NBS, EPPENDORF, GERMANY) in a humidified atmosphere in a CO2 
incubator. The cells were trypsinized (500 µl of 0.025% Trypsin in 
PBS/0.5 mM EDTA solution (Himedia)) for 2 min and passaged to T 
flasks in complete aseptic conditions. Extracts were added to grown 
cells at concentrations of 6.25 µg, 12.5µg,25 µg,50 µg and 100µg 
from a stock of 1 mg/ml 0.1% DMSO and incubated for 24 h. The % 
difference in viability was determined by standard MTT assay after 
24 h of incubation [37]. 
Cell viability by Trypan blue exclusion assay 
The effect of compound 7a-c on the viability of cancer cells (K562) 
was determined by trypan blue dye exclusion assay [38]. Briefly, the 
cells were plated at a density of 1x105in six-well plates followed by 
addition of different concentrations of compound (6.25, 12.5, 50 and 
100 µg in 1 ml of DMSO) or untreated cell. After incubation for every 
24 h, cells were collected and diluted in an equal volume of media 
and mixed with 20 ml of trypan blue. Cells were counted under the 
microscope using hemocytometer. All the experiments were 
performed in triplicate and yielded similar results [38].  
Trypan blue is a vital stain used to colour selectively dead tissues or 
cells blue. The live cells possess intact cell membranes that exclude 
trypan blue, whereas dead cells do not. So a viable cell will have a 
clear cytoplasm whereas a nonviable cell will have a blue cytoplasm. 
A 1:1 dilution of the cell culture suspension with a 0.4% trypan blue 
solution (1;1 dilution in PBS) was charged on the counting chamber 
of a haemocytometer and counted at 40x (Olympus CH 20). Stained 
cells and total cells were counted to the percentage of viable cells 
was calculated. Control was also treated in the same manner fig. 2. 
 
% of viability = [A/(A+B) ×100 
 
A = number of viable cells 
A+B = total number of viable and dead cell 
Cell proliferation by MTT assay 
MTT is a colorimetric assay that measures the reduction of yellow 
3-(4, 5dimethythiazol-2-yl)-2, 5-diphenyl tetrazolium bromide 
(MTT) by mitochondrial succinate dehydrogenase. The MTT enters 
the cells and passes into the mitochondria where it is reduced to 
an insoluble, coloured (dark purple) formazan product. The cells 
are then solubilised with an organic solvent Dimethyl sulfoxide 
(Himedia) and the released, solubilized formazan product was 
measured at 570 nm. Since the reduction of MTT can only occur in 
metabolically active cells the level of activity is a measure of the 
viability of the cells [38]. 
The cell culture suspension was washed with 1x PBS and then added 
30 µl of MTT solution to the culture (MTT-5 mg/ml dissolved in 
PBS). It was then incubated at 37 °C for 3 h. MTT was removed by 
washing with 1x PBS and 200 µlof DMSO was added to the culture. 
Incubation was done at room temperature for 30 min until the cell 
got lysed and colour was obtained. The solution was transferred to 
centrifuge tubes and centrifuged at top speed for 2 min to 
precipitate cell debris. Optical density was read at 570 nm using 
DMSO as blank in an ELISA reader (LISASCAN, Erba). All the 
experiments were performed in triplicate and yielded similar results 
fig. 3.  
LDH release assay 
The lactate dehydrogenase (LDH) release is an indicator of 
membrane integrity and thus cell injury [39, 40]. LDH assay was 
performed to evaluate the LDH release to the media following 
treatment with the 7a-h (6.25, 12.5, 25, 50 and 100 μg) on K562 for 
24 h and it was measured using standard protocols. The intracellular 
LDH was determined after lysing the cells by rapid freezing and 
thawing in liquid nitrogen. The LDH release was measured at an 
absorbance of 490 nm. The percentage of LDH release was 
calculated as: (LDH activity in media)/(LDH activity in media þ 
intracellular LDH activity) X100%. Results are presented as a 
percentage of LDH release subtracting the control values from 
treated ones. All the experiments were performed in triplicate fig. 4.  
RESULTS AND DISCUSSION 
From medicinal chemistry perspective, phenothiazines are 
important groups of condensed three ring heterocycles. 
Phenothiazine derivatives and their hetero analogues containing 1, 
4-thiazine structural fragment, show diverse biological activities. 
Phenothiazine derivatives that contain aminoalkyl substituent at the 
thiazine nitrogen atom used as antipsychotic and antihistamine 
drugs. In the present work to start with a series of phenothiazine 
derivatives 7a-h were selected. 
K562 cell line protein structures were derived from PDB and used a 
target for docking simulation. To investigate if these compounds 
have a similar mechanism as BCR-ABL kinase inhibitors, docking 
was performed using Argus lab software. The crystal structure of 
protein T3151 mutated BCR-ABL kinase was refined from the crude 
PDB structure and then saved as mole file to be used for docking 
simulation. Compounds 7a-h was constructed on chemdraw 8.0. 
Structure and the 2D structure of the selected compounds were 
converted to their 3D from, and then energy minimized and saved as 
mol. The observed negative value for the docking score energy 
(table 2) indicate the binding affinity of these compounds into 
T3151 mutated BCR-ABL kinase, this may give a reasonABLe 
explanation for their high activity. 
These detections of ligand-binding sites are often the starting point 
for protein function identification and drug discovery. In our study, 
Meta pocket active site finder predicted the active site of the K562 
cell line protein. The active sites of K562 cell protein comprise of 
amino acids which are hydrophobic and become the main 
contributors to the receptor-ligand interaction. 
In the binding pocket the Active site residues of T3151 ABL mutant 
are Ala350, Ala365, Ala366, Asn297, Arg483, Asp381, Asp421, 
Asp482, Cys305, Cys369, Gln477, Gly303, Gly372, Gly383, Gly426, 
Ile315, Ile347, Leu302, Leu364, Met458, Ser265, Thr267, Trp405, 
Tyr320 and Val299.  
Energy analysis in table 1 demonstrated the lower binding energy of 
inhibitors 7a-h with T3151 mutated BCR-ABL kinase under the 
participation of Van der Walls force, hydrogen bonds and 
hydrophobic interaction during the process of enzyme-inhibitor 
interaction. Docking studies yielded crucial information concerning 
the orientation of the inhibitors in the binding pocket of the target 
protein. The binding affinity of the K562 cell line protein with the 
compounds 7a-h was measured by kcal/mol. 
The fig. 1 shows the hydrophilic and hydrophobic interactions of the 
ligands with the protein. From the table 1 it was learned that 
compounds 7a, 7b and 7c with H, chloro and bromo substituent 
respectively exhibited a reasonably good scores-12.716, 12.3456 
and 14.665.0186 k cal/mol. These three compounds were selected 
for further in-vitro studies. 
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Table 1: Docking scores, of the 7a-h ligands with tyrosine kinase inhibitors 
S. No. Compound Score 
1  7a -12.751 
2  7b -12.363 
3  7c -14.663 
4  7d -12.469 
5  7e -11.454 
6  7f -11.236 
7  7g -12.690 
8  7h -12.536 
All the cyclohexanone derivatives of phenothiazine chalcones (7a-h) showed good docking scores. The table 2 shows the docking scores, H-bonded 
interactions and the amino acids surrounding the ligand. 
 
Table 2: Docking scores, H-bond interactions’ and surroundings amino acids of the 7a-c ligands with tyrosine kinase inhibitors 
Compound Score H-bond 
interaction 
Surrounding amino acid 
7a -
12.7515 
No H-Bonding GLU-466,459,462,GLY-463, 426, PRO-465,461, CYS-464, ARG-460, 473, LEU-429, MET-458,472, 
TYR-469 
7b -12.363 VAL-268 ALA-269,ASP-233,ILE-315, 314, LEU-301, 266, 302, GLN-300, GLU-236, GLY-303, VAL-268, 304, 
THR-267, TYR-264, SER-265, 
7c -
14.6632 
LYS-298, ALA-380 ALA-380, PHE-382, 317 LEU-298, 378, 372,VAL-299, GLY-250, 321, GLU-316, ILE-315, MET-318, 
THR-319 
 
Table 3: Lipinski’s rule of five parameters for 7a-h 
Compound Molecular weight Molecular formula H-bond donor H-bonding acceptor Rotatable bonds Log p 
7a 383.51 C25H21NOS 1 1 2 4.94 
7b 382.5 C25H20ClNOS 1 1 2 5.5 
7c 462.4 C25H20BrNOS 1 1 2 5.77 
7d 397.53 C26H23NOS 1 1 2 5.43 
7e 411.52 C26H21NO2S 1 2 2 4.69 
7f 401.5 C25H20FNOS 1 2 2 5.1 
7g 428.5 C25H20N2O3S 1 3 2 - 
7h 428.57 C27H26NO2S 1 1 2 4.81 
To identify whether the above-tested compounds are drug like molecules the Lipinski’s rule of five parameters like molecular weight, molecular 
formulae, a number of H-bond donor, Number of H-bond acceptors, Number of rotatable bonds and the Log P value were calculated for the 






Fig. 1: Binding of 7b with 2V7A Protein (A) Ligand seated in the 
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Scheme 1: Synthesis route of Cyclohexane derivatives of 
Phenothiazine preparation from 
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Synthesis of cyclohexane derivative of chalcone 
The chalcones 3a-c was prepared by Claisen-Schmidt condensation 
(Scheme 1) of equimolar quantities of phenothiazine methyl ketone 
1 with substituted aryl aldehydes 3a-c in the presence of alcoholic 
alkali. The analytical data, reaction conditions and the yield of the 
product 3a-c were optimized. 
 
 
Fig. 2: Viability of K562 cell against 3a-c In Trypan Blue assay 
Sample size n=3. Values expressed as mean±SEM 
 
Characterization of Cyclohexenones 7a-h 
In the UV spectra, all the compounds 7a-h gives rise to the 
characteristic peak for chalcones at 412 nm and 290 nm respectively 
for band 1and 2. In the IR spectrum of 7a-h it revealed a strong, 
sharp band at 1632 cm-1 representing carbonyl group, 1600 cm-1 
for C=C and at 3332 cm-1 for the NH stretching band. The addition of 
ethyl acetoacetate to chalcones 3a-h, leads to the generation of a 
chiral center in the 7a-h, In 1H-NMR spectrum of compound 7a the 
pair of methylene protons H-4 and H-6 of cyclohexenone moiety 
were observed as multiplets at δ 2.83 and 3.37 respectively. The CH 
(H-5) proton of Cyclohexenone ring resonated as a multiplet at δ 
2.62. H-2 carbon appears as singlet at δ 6.42. The protons present in 
the phenothiazine ring are explained as follows, H-1', 3', 4', 6', 8' 
appeared as the multiplet between δ 7.01-6.99. H-7' appeared as 
doublet at δ 6.70 with J value 8Hz. H-9' appeared as doublet at δ 6.64 
with J value 8Hz. H-2'', 6'' appeared as doublet between δ 7.22-7.19 
with J=8Hz. H-3'', 5'' appeared as multiplet between δ 6.84-6.81. The 
NH group appeared as a singlet at δ 8.57. The OCH3 group 
substituted in the aromatic ring of 7a appeared as singlet at δ 3.81. 
In 13C-NMR spectrum, C=O group present in the cyclohexenone ring 
appears at δ 199.30. C-2 appears at δ 124.49; C-3 appears at δ 
157.00. Carbons C-4 at δ 36.41, C-5 at 40.21, C-6 at 44.28. All the 
carbons present in aromatic ring appears between δ 111.58 and 
158.67. The 2D NMR spectral data also supports the proposed 
structures for the compounds. In 13CNMR spectrum, the 
cyclohexanones showed 25 signals. In the DEPT-135 spectra of the 
compound, 5a showed only 16 signals. All the quaternary carbon 
signals at δ 137.66, 141.95, 124.49, 141.05, 120.45, 157.00, 40.21, 
141.00, 199.30 disappeared. Further, it exhibits 13 CH signals, 2 
(CH2) methylene signals and one methyl signal. 
 
 
Fig. 3: MTT assay result against K562 cell line 
Sample size n=3. Values expressed as mean±SEM 
 
 
Fig. 4: Lactate dehydrogenase leakage assay  
Sample size n=3. Values expressed as mean±SEM
 
Table 3: IC50 Values In trypan Blue assay and MTT assay 
S. No Compound IC50(µg/ml) 
Trypan blue assay MTT assay  
1 7a 60.02±0.37 41.01±0.43 
2 7b 42.3±0.22 38.98±0.18 
3 7c 36.06±0.32 36. 75±.0.26 
Values are expressed as mean±SD (standard deviation), sample size n=3 
 
CONCLUSION  
Compounds 7a-h was docked with tyrosine kinase inhibitor and 
their scores determined. All the compounds exhibited good scores 
showing the effective interaction of this group of ligands with the 
target. Compounds 7a-c are found to be having excellent scores. 
Lipinski’s rule of five has been applied on these compounds to 
determine the drug likeliness of these compounds. All the 
compounds have drug like properties. The compounds 7a-c was 
tested for antiproliferative effect against K562 cell lines by MTT 
assay LDH assay and Trypan blue assay. All the compounds 7a-h 
behaves as 3(rd) generation inhibitors for the treatment of patients 
with Chronic myelogenous leukemia (CML). These can act as a 
template for the further development and optimization studies. 
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